The CHRYSALIS Study is evaluating the safety and effectiveness of an investigational medication for different groups of people with NSCLC. Participants in the groups that are currently enrolling need to have NSCLC with either a primary gene mutation known as the MET Exon 14 skipping mutation or NSCLC with types known as adenocarcinoma or squamous cell carcinoma without certain gene mutations (EGFR and ALK) on tumor testing. Learn more about the CHRYSALIS research study here.

The MARIPOSA Study is evaluating the safety and effectiveness of one investigational medication or a combination of two investigational medications. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution.

The MARIPOSA 2 Study is evaluating the safety and effectiveness of a combination of two investigational medications in addition to approved chemotherapy. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution. Learn more about the MARIPOSA 2 research study here.

The PAPILLON Study is evaluating the safety and effectiveness of an investigational medication in combination with chemotherapy. Participants in this study need to have a rare form of EGFR mutation called an Exon 20 insertion. Learn more about the PAPILLON research study here.